Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Supermax Corporation Berhad (7106.KL)
Sungai Buloh, MY
Supermax Corporation Berhad operates as an investment holding entity primarily focused on the manufacture, sale, and distribution of medical gloves and contact lenses within Malaysia. Its product portfolio includes diverse natural rubber and nitrile latex gloves, in addition to personal protective equipment. Beyond its core manufacturing, Supermax engages in the import, export, and trading of latex gloves, biomass energy generation, the marketing and distribution of various healthcare items and medical devices, and property investments. The company's offerings, branded as Supermax, Aurelia, and Maxter, are supplied to a professional clientele comprising laboratories, pharmacists, hospitals, physicians, and surgeons. Demonstrating a significant international presence, Supermax exports its products to approximately 165 countries globally, spanning key regions such as the United States, the European Union, the Middle East, Asia, and the South Pacific. Founded in 1987, the firm maintains its headquarters in Sungai Buloh, Malaysia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.56% | -4.55% | +0.00% | +12.50% | -14.86% | -5.97% | -54.35% | -59.35% | -90.54% | -34.61% | +128.41% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 0 | 0 |
| Hold | 2 | 0 |
| Sell | 2 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+21.0% ★ Q3'25: -8.5% (vs Q3'24)
-
EPS growth Medical - Instruments & Supplies: +16.3%+8.6% Q3'25: -107.1% (vs Q3'24)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-20.0% Q3'25: -8.1% (vs Q3'24)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-25.8% Q3'25: -68.8% (vs Q3'24)
-
ROIC Medical - Instruments & Supplies: +6.0%-6.0% Q3'25: -16.5% (vs Q3'24)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.2% ★ Q3'25: +0.5% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×-1.21× Q3'25: -0.29× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 4 Rev. Ana. 4 EPS Ana. |
Jun 2027 4 Rev. Ana. 4 EPS Ana. |
Jun 2028 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.35B
est.
|
1.13B
est: 1.17B (-3.4%)
|
1.30B
est: 1.40B (-7.0%)
|
1.54B
est: 1.47B (+4.4%)
|
2.13B
est: 2.31B (-7.6%)
|
7.16B
est: 7.10B (+0.9%)
|
2.69B
est: 2.89B (-7.1%)
|
821.09M
est: 1.00B (-18.2%)
|
646.17M
est: 1.01B (-35.7%)
|
781.85M
est: 854.60M (-8.5%)
|
913.68M
853.76M – 1.09B
+6.9% YoY
|
1.07B
951.33M – 1.27B
+16.7% YoY
|
1.28B
1.17B – 1.52B
+20.2% YoY
|
| EBITDA |
188.33M
est.
|
160.23M
est: 162.34M (-1.3%)
|
217.64M
est: 195.16M (+11.5%)
|
237.12M
est: 204.96M (+15.7%)
|
740.77M
est: 320.81M (+130.9%)
|
5.06B
est: 987.25M (+412.7%)
|
1.15B
est: 402.42M (+185.9%)
|
-96.92M
est: 139.65M (-169.4%)
|
-105.87M
est: 139.81M (-175.7%)
|
-122.95M
est: 118.88M (-203.4%)
|
127.10M
118.77M – 151.02M
+6.9% YoY
|
148.33M
132.34M – 176.22M
+16.7% YoY
|
178.36M
162.62M – 211.91M
+20.2% YoY
|
| EBIT |
94.30M
est.
|
119.00M
est: 81.29M (+46.4%)
|
175.88M
est: 97.72M (+80.0%)
|
192.12M
est: 102.63M (+87.2%)
|
679.11M
est: 160.64M (+322.8%)
|
4.99B
est: 494.33M (+910.1%)
|
1.08B
est: 201.50M (+434.3%)
|
-182.27M
est: 69.92M (-360.7%)
|
-174.27M
est: 70.00M (-349.0%)
|
-201.43M
est: 59.53M (-438.4%)
|
63.64M
59.47M – 75.62M
+6.9% YoY
|
74.27M
66.26M – 88.24M
+16.7% YoY
|
89.31M
81.43M – 106.11M
+20.2% YoY
|
| Net Income |
117.68M
est.
|
67.20M
est: 84.86M (-20.8%)
|
106.66M
est: 120.35M (-11.4%)
|
123.11M
est: 121.08M (+1.7%)
|
524.80M
est: 349.97M (+50.0%)
|
3.82B
est: 3.43B (+11.3%)
|
718.91M
est: 684.46M (+5.0%)
|
-140.87M
est: -144.63M (+2.6%)
|
-175.62M
est: -24.83M (-607.2%)
|
-160.40M
est: -92.48M (-73.4%)
|
-27.82M
-38.41M – -19.70M
+69.9% YoY
|
2.77M
-2.77M – 5.55M
+110.0% YoY
|
25.07M
22.19M – 31.20M
+803.7% YoY
|
| SGA |
203.23M
est.
|
64.8K
est: 175.18M (-100.0%)
|
64.8K
est: 210.59M (-100.0%)
|
64.8K
est: 221.17M (-100.0%)
|
405.12M
est: 346.19M (+17.0%)
|
623.80M
est: 1.07B (-41.4%)
|
446.32M
est: 434.25M (+2.8%)
|
408.42M
est: 150.70M (+171.0%)
|
—
est: 150.87M (-100.0%)
|
—
est: 128.29M (-100.0%)
|
137.16M
128.16M – 162.96M
+6.9% YoY
|
160.06M
142.81M – 190.16M
+16.7% YoY
|
192.47M
175.48M – 228.67M
+20.2% YoY
|
| EPS |
0.04
est.
|
0.02
est: 0.03 (-29.2%)
|
0.03
est: 0.04 (-19.6%)
|
0.04
est: 0.04 (-7.1%)
|
0.08
est: 0.11 (-30.2%)
|
1.19
est: 1.11 (+6.6%)
|
0.23
est: 0.22 (+2.1%)
|
-0.04
est: -0.05 (+5.2%)
|
-0.06
est: -0.01 (-606.3%)
|
-0.05
est: -0.03 (-73.3%)
|
-0.01
-0.01 – -0.01
+69.9% YoY
|
0.00
0.00 – 0.00
+110.0% YoY
|
0.01
0.01 – 0.01
+803.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 16.5K | 0.42% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 574.3K | 0.06% |
| 3 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 5.1K | 0.33% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 32.9K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 14.6K | 0.48% |
| 6 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 4.1K | 0.33% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.62M | 0.06% |
| 8 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 258.5K | 0.33% |
| 9 | Avantis Emerging Markets Value ETF AVES | 0.00% | 7.9K | 0.36% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 24.0K | 0.10% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kim Sim Thai | Founder & Executive Chairman | 159.5K | male |
| Chee Keong Tan | Chief Executive Officer & Senior Executive Director | 123.5K | male |
| Hooi Pin Lau | Company Secretary | — | — |
| Tong Lang Tan | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7106.KL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
